BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vogl M, Rosenmayr A, Bohanes T, Scheed A, Brndiar M, Stubenberger E, Ghanim B. Biomarkers for Malignant Pleural Mesothelioma-A Novel View on Inflammation. Cancers (Basel) 2021;13:658. [PMID: 33562138 DOI: 10.3390/cancers13040658] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhang Y, Li R, Gu Y, LiZhu Y, Liu X, Zhang S. Clinical, Laboratory, Histological, Radiological, and Metabolic Features and Prognosis of Malignant Pleural Mesothelioma. Medicina (Kaunas) 2022;58. [PMID: 36557076 DOI: 10.3390/medicina58121874] [Reference Citation Analysis]
2 Ghanim B, Baier D, Pirker C, Müllauer L, Sinn K, Lang G, Hoetzenecker K, Berger W. Trabectedin Is Active against Two Novel, Patient-Derived Solitary Fibrous Pleural Tumor Cell Lines and Synergizes with Ponatinib. Cancers (Basel) 2022;14. [PMID: 36428694 DOI: 10.3390/cancers14225602] [Reference Citation Analysis]
3 Faccioli E, Terzi S, Giraudo C, Zuin A, Modugno A, Labella F, Zambello G, Lorenzoni G, Schiavon M, Gregori D, Pasello G, Calabrese F, Dell’amore A, Rea F. Sarcopenia as a Predictor of Short- and Long-Term Outcomes in Patients Surgically Treated for Malignant Pleural Mesothelioma. Cancers 2022;14:3699. [DOI: 10.3390/cancers14153699] [Reference Citation Analysis]
4 Rovers S, Janssens A, Raskin J, Pauwels P, van Meerbeeck JP, Smits E, Marcq E. Recent Advances of Immune Checkpoint Inhibition and Potential for (Combined) TIGIT Blockade as a New Strategy for Malignant Pleural Mesothelioma. Biomedicines 2022;10:673. [PMID: 35327475 DOI: 10.3390/biomedicines10030673] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Harber J, Kamata T, Pritchard C, Fennell D. Matter of TIME: the tumor-immune microenvironment of mesothelioma and implications for checkpoint blockade efficacy. J Immunother Cancer 2021;9:e003032. [PMID: 34518291 DOI: 10.1136/jitc-2021-003032] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
6 Pouliquen DL, Kopecka J. Malignant Mesothelioma. Cancers (Basel) 2021;13:3447. [PMID: 34298661 DOI: 10.3390/cancers13143447] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Lorenzini E, Ciarrocchi A, Torricelli F. Molecular Fingerprints of Malignant Pleural Mesothelioma: Not Just a Matter of Genetic Alterations. J Clin Med 2021;10:2470. [PMID: 34199544 DOI: 10.3390/jcm10112470] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
8 Huang Y, Meng Q. [Research Progress of Immune Checkpoint Inhibitors 
in Malignant Pleural Mesothelioma]. Zhongguo Fei Ai Za Zhi 2021;24:441-6. [PMID: 34157803 DOI: 10.3779/j.issn.1009-3419.2021.102.18] [Reference Citation Analysis]